🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsBeen on the reta waiting list for months - anyone heard anything?

Been on the reta waiting list for months - anyone heard anything?

rick_sfbay Thu, Apr 16, 2026 at 7:16 PM 23 replies 1,035 viewsPage 1 of 5
rick_sfbay
Member
289
1,234
Jan 2025
San Francisco, CA
Apr 16, 2026 at 7:16 PM#1

Reading the retatrutide phase 2 data properly rather than the headline, and the 24% figure is doing a lot of work that the confidence interval does not support as firmly as people think.

What would genuinely help is knowing why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose.

Tell me what I have not thought of.

24 19mike_mealprep, NicoleRaleigh, james_edin and 21 others
Reply Quote Save Share Report
amsterdam_pete
Senior Member
1,567
6,789
Feb 2024
Netherlands
Apr 16, 2026 at 7:28 PM#2

Taking the question as asked, rather than the general version of it. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

23 18ZaraB_AL, JakeSmashed95, NauseaFreeNow and 20 others
Reply Quote Save Share Report
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
Apr 16, 2026 at 7:40 PM#3
amsterdam_pete said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

amsterdam_pete has the substance of this right. The condition it depends on is worth stating. The glucagon component looks paradoxical and is not. Glucagon receptor agonism raises energy expenditure and drives hepatic fatty-acid oxidation, and its hyperglycaemic tendency is offset by the GLP-1 arm's insulin secretagogue effect. Net result: intake down from GLP-1/GIP, expenditure up from glucagon, glycaemia neutral or improved. It is a balancing act, and it is why the liver-fat results are the most interesting part of the dataset.

22 17PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 19 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
ben_calgary
Member
245
1,123
Oct 2024
Calgary, CA
Apr 16, 2026 at 7:52 PM#4
rick_sfbay said:
Reading the retatrutide phase 2 data properly rather than the headline, and the 24% figure is doing a lot of work that the confidence interval does…

Second this. Nothing to add that would improve it.

Last edited: Apr 17, 2026 at 1:52 AM
21 16JakeSmashed95, NauseaFreeNow, SteveThurs and 18 others
Reply Quote Save Share Report
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Apr 16, 2026 at 8:57 PM#5

Adding the clinical framing, because it changes how the question reads. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

20 15chris_chi24, tampaLisa73, KarenAZ_mom and 17 others
Reply Quote Save Share Report
1235

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register